News Release 

Immunotherapy combo achieves reservoir shrinkage in HIV model

CTLA-4 and PD-1 inhibitors together strongly reactivate immune system

Emory Health Sciences

Stimulating immune cells with two cancer immunotherapies together can shrink the size of the viral "reservoir" in SIV (simian immunodeficiency virus)-infected nonhuman primates treated with antiviral drugs, Emory University researchers and their colleagues have concluded. The reservoir includes immune cells that harbor virus despite potent antiviral drug treatment.

The findings, reported in Nature Medicine, have important implications for the quest to cure HIV because reservoir shrinkage has not been achieved consistently before. However, the combination treatment does not prevent or delay viral rebound once antiviral drugs are stopped. Finding an HIV cure is of critical importance as, although antiretroviral therapy can reduce the amount of circulating virus to undetectable levels, problematic issues remain such as social stigma in addition to the long-term toxicity and cost of antiretroviral drugs.

"It's a glass-half-full situation," says senior author Mirko Paiardini, PhD. "We concluded immune checkpoint blockade, even a very effective combination, is unlikely to achieve viral remission as a standalone treatment during antiretroviral therapy."

He adds the approach may have greater potential if combined with other immune-stimulating agents. Or it could be deployed at a different point -- when the immune system is engaged in fighting the virus, creating a target-rich environment. Other HIV/AIDS researchers have started to test those tactics, he says.

Paiardini is an associate professor of pathology and laboratory medicine at Emory University School of Medicine and a researcher at Yerkes National Primate Research Center. The study performed in nonhuman primates, considered the best animal model for HIV studies, was carried out in collaboration with co-authors Shari Gordon and David Favre at the University of North Carolina at Chapel Hill and GlaxoSmithKline; Katharine Bar at the University of Pennsylvania; and Jake Estes at Oregon Health & Science University.

Although antiviral drugs are available that can suppress HIV to the point of being undetectable in blood, the virus embeds itself in the DNA of immune cells, frustrating efforts to root it out. Only two individuals have ever achieved what their doctors consider a durable cure, and they went through a bone-marrow transplant for leukemia or lymphoma -- not widely applicable.

Paiardini and his colleagues reasoned chronic viral infection and cancer produce similar states of "exhaustion": immune cells (T cells) that could fight virus or cancer are present, but unable to respond. In long-term HIV or SIV infection, T cells harboring the virus display molecules on the cell surface that make them targets for checkpoint inhibitors, cancer immunotherapy drugs that are designed to counteract the exhausted state. In the context of HIV infection, these types of drugs have been tested to a limited extent in people living with HIV who were being treated for cancer.

In the Nature Medicine paper, the researchers used antibodies to block the surface molecules CTLA-4 and PD-1. In monkeys that received both CTLA-4- and PD-1-blocking agents, researchers observed a stronger activation of T cells, compared to only PD-1 blockade. DNA sequencing of viruses in the blood revealed a broader range of viruses were reactivated with the combination, compared to single checkpoint inhibitors.

"We observed that combining CTLA-4- and PD-1 blockade was effective in reactivating the virus from latency and making it visible to the immune system," Paiardini says.

In previous studies, limited shrinkage of the viral reservoir has been seen only inconsistently with single checkpoint inhibitors or other immune-stimulating agents. Only combination-treated animals showed a consistently measurable and significant reduction in the size of the viral reservoir. The researchers measured this with "DNAscope," an imaging technique to visualize infected cells within tissues. Additionally, researchers quantified the frequency of CD4 cells, the main reservoir of HIV and SIV, harboring intact viral DNA capable of replicating.

Despite this effect, once antiviral drugs were stopped, the virus still came back to the same level in combination-treated animals.

"We believe this is due to having much less viral antigens around after long-term antiretroviral therapy, compared with the situation in cancer," says Justin Harper, lab manager and first author of the paper. "This makes it much more difficult for the immune system to recognize and kill those cells."

A note of caution: the equivalent combination of CTLA-4 and PD-1 blockade in humans has been tested in the context of cancer treatment. While the two drug types can be more effective together, patients sometimes experience adverse side effects: severe inflammation, kidney damage, or liver damage.

In the Nature Medicine paper, the combination-treated animals did not experience comparable adverse events, the researchers reported. Further investigation is necessary to determine whether the combination of checkpoint inhibitors exhibits an acceptable toxicity profile in people living with HIV without cancer.

Paiardini credits the Yerkes National Primate Research Center Animal Resources team for their dedicated care of the animals involved in the study. HIV studies are complex and long-term, so animal care is the backbone of being able to conduct such research focused on improving human health.

###

Emory's Center for AIDS Research (P30AI050409), the Consortium for Innovative AIDS Research in Nonhuman Primates (UM1AI124436), the National Institute of Allergy and Infectious Diseases (R01AI116379, R21/R33AI116171), the Collaboratory of AIDS Researchers for Eradication (UM1AI126619), GlaxoSmithKline, Qura Therapeutics, the NIH director's Office of Research Infrastructure Programs (P51OD011132, P51OD011092), and the National Cancer Institute (HHSN261200800001E) supported this research.

Grant amounts (direct + indirect):

P30AI050409 $4,129,580/yr
UM1AI124436 $7,450,948/yr
R01AI116379 $783,714/yr
R21/R33AI116171 $480,497/yr
UM1AI126619 $4,789,982/yr
P51OD011132 $10,540,602/yr
P51OD011092 $13,153,537/yr

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.